• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lycera names Paul Sekhri president and CEO

Lycera names Paul Sekhri president and CEO

February 5, 2015
CenterWatch Staff

Lycera, a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, has named Paul Sekhri president, CEO and a member of the board of directors, effective immediately. Sekhri brings more than 25 years of operational experience in the life sciences industry, including business development and strategy, general management, drug development, and commercial strategy.  He succeeds Kathleen M. Metters, Ph.D., who currently serves as senior advisor to the company.

Previously, Sekhri was senior vice president, integrated care at Sanofi, where he led the creation of innovative solutions and business models to meet patient needs. He was group executive vice president, global business development and chief strategy officer at Teva Pharmaceutical Industries. Prior to this, Sekhri was operating partner and head, biotech ops group at TPG Biotech, the life science venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life science firms.

Sekhri founded and was president and CEO of Cerimon Pharmaceuticals, focused on autoimmune diseases and pain management, and prior to that, he was president and chief business officer of Ariad Pharmaceuticals. Earlier in his career, he held senior positions at Novartis Pharma, including as senior vice president and head, global search and evaluation and M&A. He also held managerial positions at Millipore and PerSeptive Biosystems.  

Sekhri has worked as a director of numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as board advisor to IMS Health. Currently, he is director of Veeva Systems.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing